Kevin Zhang, Deputy Co-COO and SVP of Business Development and Global Sales at TSMC (TSM.US), remarked that the company plans to establish a chip packaging plant in Arizona by 2029. It will actively expand the production capacity of its Arizona facilities, aiming to build CoWoS and 3D-IC capacity by 2029.

By far, Apple (AAPL.US) and Nvidia (NVDA.US) have been sourcing chips from TSMC's Arizona plant, but many of these chips still need to be shipped back to Taiwan for packaging. Amkor Technology (AMKR.US) and TSMC previously announced in 2024 that they would collaborate to introduce several of TSMC's advanced packaging technologies to Arizona.
~

AASTOCKS Financial News
Website: www.aastocks.com

Tesla (TSLA.US) announced after market close on Wednesday that its net profit for 1Q26 lifted 17% YoY to USD477 million. Adjusted EPS was USD0.41, above market expectations of USD0.37. Following the results announcement, the stock shot up nearly 4% in after-hours trading.

Revenue for the quarter mounted 16% YoY to USD22.39 billion, slightly below market expectations of USD22.64 billion.
~

AASTOCKS Financial News
Website: www.aastocks.com

US President Donald Trump's extension of the US ceasefire agreement with Iran, paired rosy corporate earnings, boosted market sentiment. The Nasdaq and the S&P 500 both closed at record highs. US equities advanced across the board on Wednesday.

The S&P 500 erased its losses for the week, adding 73 points, or 1.1%, to close at 7,137. The Nasdaq hit an intraday record high of 24,660 and finished up 397 points, or 1.6%, at 24,657. The DJIA shot up 340 points, or 0.7%, to close at 49,490.

Apple (AAPL.US) spiked 2.6%, leading gains among the "Magnificent Seven", as CEO Tim Cook will serve long-term as chairman. Alphabet (GOOG.US) and Amazon (AMZN.US) each climbed more than 2%.
~

AASTOCKS Financial News
Website: www.aastocks.com

HONG KONG, April 22, 2026 /PRNewswire/ -- Newborn Town, a leading global social entertainment company, released its unaudited operating data for the first quarter of 2026.

For the three months ended 31 March 2026, the company's total revenue is estimated to reach RMB 2,030 million to RMB 2,130 million, reflecting a year-on-year increase of approximately 33.0% to 39.6%. Revenue from social networking business amounted to approximately RMB 1,785 million to RMB 1,865 million, representing a year-on-year increase of approximately 31.3% to 37.2%.

Revenue from innovative business recorded approximately RMB 245 million to RMB 265 million, representing a year-on-year growth of approximately 46.7% to 58.7%, maintaining strong growth momentum.

Social Networking Business Deepened Its Competitive Moat as Flagship Products Continue to Strengthen Market Leadership

According to the announcement, the steady growth of social networking business revenue was driven by the company's continued global expansion and the deep integration of AI across the entire business chain, supporting the sustained growth of its flagship products.

In the first quarter of 2026, the company continued to advance its successful strategy of replicating its product operations and market expansion experiences, further strengthening its leadership in core markets such as the MENA region and Southeast Asia, while using flagship products as strategic pioneers to accelerate expansion into high-growth and high-value markets including Latin America, Europe, Japan, and South Korea, further enhancing its global social entertainment footprint.

In 2026, the Company's flagship products continued to deliver strong performance. The game-oriented social platform TopTop further improved its market position across GCC countries. According to data from Sensor Tower, in Q1, TopTop ranked 6th in the social apps category on the App Store's revenue rankings for the Middle East.

In new markets, TopTop continued to expand its footprint. TopTop made solid progress in high-value markets such as Japan and Europe, ranking among the Top 10 free casual games on the Japanese App Store multiple times during the first quarter.

Meanwhile, TopTop continues to leverage its UGC-driven ecosystem to expand into developed markets. It has grown into a widely adopted app in GCC markets such as Saudi Arabia and ranks among the leading products in its category globally.

The company's diverse-audience social networking business also maintained steady growth. HeeSay, the company's global community platform for diverse audiences, further strengthened its presence in Southeast Asia, consistently ranking among the Top 10 grossing social apps on the App Store in countries such as Vietnam and the Philippines.

A research report by Huaxi Securities noted that social networking and gaming apps continue to outperform across downloads, user engagement, and monetization. With its expanding global footprint, Newborn Town is well positioned to continue benefiting from these long-term industry trends, further reinforcing the certainty of its long-term growth trajectory.

Innovative Business Gained Strong Momentum, with AI Driving Rapid Revenue Growth

The company's innovative business also demonstrated strong growth momentum in the first quarter of 2026. According to the announcement, the growth in revenue from the innovative business segment was driven by the rapid expansion of the short drama business, supported by AI-powered content production and operations.

During the period, the company's short drama business progressed steadily across multiple overseas markets including Europe and North America, validating its full-chain capabilities in content creation and blockbuster content incubation.

Building on this foundation, Newborn Town is actively expanding into AI short dramas, leveraging AI technology to amplify content production, diversify genres, and optimize production costs, positioning short drama as a new growth engine for the innovative business.

Recently, the Company's short-form drama business was officially integrated with Seedance 2.0, becoming one of its first partner platforms. At the same time, through joint operations with platforms such as TikTok, the global reach of its short-form content has continued to expand. According to TikTok's first-quarter revenue-sharing report for short dramas, one of the Company's hit titles ranked No. 2 on the platform by first-month revenue.

In recent years, the company has continued to deepen the application of AI technologies across core business scenarios, comprehensively empowering R&D, operations, and commercialization efficiency. Its self-developed multimodal algorithm model, Boomiix, continues to upgrade, improving the accuracy of social matching and the intelligence of operations.

The company's Siyu AI, an internal data intelligence platform, significantly shortened turnaround times for data queries, anomaly analysis, and report generation. Its proprietary AI-powered design platform KIVI has also greatly enhanced both the efficiency and diversity of content production, including virtual gifts and marketing creatives.

In addition, the company continued to expand into consumer-facing AI applications by launching Aippy, exploring new ways to create emotional value through AI. To date, Aippy has surpassed 2 million cumulative downloads. Beyond this, the Company has launched NUSD Pay, an AI agent-based payment solution, which has completed core system development and entered the commercialization stage.

The company announced to allocate approximately HK$ 300 million over the next two years for share repurchases, which may be used for the company's employee equity incentive plans or cancellation in accordance with applicable laws, regulations, and listing rules. The Board believes that implementing share repurchases under the current circumstances reflects confidence in the company's long-term business outlook and will ultimately benefit the company while creating value for shareholders.

On 6 March, Newborn Town was officially included in the list of eligible securities under the Stock Connect, broadening access for mainland investors. Since its inclusion, the company has seen significantly stronger market attention and trading activity. As of April 21, its average daily trading value exceeded HKD 180 million, approximately doubling compared to the three months prior to inclusion.

Following its inclusion in Stock Connect, the Company's shareholder base has continued to diversify, while its market presence has further strengthened, providing solid support for its long-term growth.

BEIJING, April 22, 2026 /PRNewswire/ -- New Oriental Education & Technology Group Inc. (the "Company" or "New Oriental") (NYSE: EDU/ 9901.SEHK), a provider of private educational services in China, today announced its unaudited financial results for the third fiscal quarter ended February 28, 2026, which is the third quarter of New Oriental's fiscal year 2026.

Financial Highlights for the Third Fiscal Quarter Ended February 28, 2026

• Total net revenues increased by 19.8% year over year to US$1,417.3 million for the third fiscal quarter of 2026. 
• Operating income increased by 44.8% year over year to US$180.3 million for the third fiscal quarter of 2026.
• Net income attributable to New Oriental increased by 45.3% year over year to US$126.8 million for the third fiscal quarter of 2026.

Key Financial Results

Operating Highlights for the Third Fiscal Quarter Ended February 28, 2026

Michael Yu, New Oriental's Executive Chairman, commented, "We are pleased to share of continued acceleration in our revenue growth year over year in the third fiscal quarter of 2026. Revenues from overseas test preparation increased by approximately 7.4%. In addition, our domestic test preparation business targeting adults and university students grew by approximately 14.5% year over year, followed by a growth of 23.3% year over year for our new educational business initiatives. Our non-academic tutoring courses was rolled out in around 60 cities, attracting approximately 458,000 student enrollments this quarter. Concurrently, our intelligent learning system and devices were adopted in around 60 cities, with approximately 367,000 active paid users. We are sharpening our focus on our core education business, prioritizing enhancements of teaching standards and product quality. Simultaneously, we will optimize our cost structure and operational efficiency to drive high-quality, efficient, and sustainable growth. We have also established a comprehensive customer service system spanning all departments, which now serves over 330,000 families in 12 cities. This infrastructure strengthens customer loyalty and retention, unlocks cross-selling potential, maximizes customer lifetime value all while lowering both customer acquisition and marketing costs. We remain committed to enhancing our brand influence and creating long-term value for our customers and shareholders."

Chenggang Zhou, New Oriental's Chief Executive Officer, added, "In this fiscal quarter, we continued to execute our strategy of disciplined capacity expansion, balancing revenue growth with operational efficiency. As part of our ongoing commitment, we further enhanced our OMO teaching system and deepened AI integration across our education ecosystem. This quarter, we made notable progress in embedding AI into existing educational offerings, refining AI‑powered products, and deploying AI to improve operational efficiency and support for our teaching staff. In addition, East Buy remains committed to offering premium products and exceptional services to Chinese families. We launched multiple live-streaming accounts on Douyin, creating a comprehensive multi-account matrix including East Buy Home, East Buy Fruit & Vegetables, East Buy Nutrition & Health, followed by other vertical channels. We also optimized live-streaming content and introduced innovative initiatives such as live streamer recruitment campaign and supplier conferences. East Buy will continue advancing private label development, membership ecosystem, offline expansion, and operational efficiency to drive sustainable long-term growth."

Stephen Zhihui Yang, New Oriental's Executive President and Chief Financial Officer, commented, "We are encouraged by the continued year over year improvement in our Non-GAAP operating margin in this quarter. This was primarily driven by enhanced operational efficiency and improved utilization within our educational business. We recorded a quarterly Non-GAAP operating margin of 14.3%, up by 230 basis points compared to the same period last fiscal year. Looking ahead, we remain committed to executing the cost and efficiency initiatives already underway across key business lines. Targeted structural optimizations have enabled fixed cost reduction and driven greater operational efficiency, steadily elevating our operating profit margins and strengthening our foundation for sustainable, profitable growth."

Update on Shareholder Return for the Fiscal Year 2026

In October 2025, the Company announced that, pursuant to its previously adopted three-year shareholder return plan, the board of directors had approved an ordinary dividend of US$0.12 per common share, or US$1.20 per ADS, to be distributed in two installments as part of the shareholder return for the fiscal year 2026. The first installment has been fully paid to shareholders and ADS holders. The board has now approved the payment of the second installment of US$0.06 per common share, or US$0.6 per ADS, to holders of common shares and holders of ADSs of record as of the close of business on May 15, 2026, Beijing/Hong Kong Time and New York Time, respectively, with the expected payment date to be on or around June 2, 2026 and June 5, 2026 for holders of common shares and holders of ADSs, respectively.

For holders of common shares, in order to qualify for the second installment of the dividend, all valid documents for the transfer of shares accompanied by the relevant share certificates must be lodged for registration with the Company's Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong no later than 4:30 p.m. on May 15, 2026 (Beijing/Hong Kong Time). Dividend to be paid to the Company's ADS holders through the depositary bank will be subject to the terms of the deposit agreement.

Additionally, as part of the shareholder return for the fiscal year 2026, the Company also announced in October 2025 a share repurchase program, under which the Company is authorized to repurchase up to US$300 million of its ADSs or common shares over the subsequent 12 months. As of April 21, 2026, the Company had repurchased a total of approximately 3.3 million ADSs for an aggregate consideration of approximately US$184.3 million from the open market under this share repurchase program.

Financial Results for the Third Fiscal Quarter Ended February 28, 2026

Net Revenues

For the third fiscal quarter of 2026, New Oriental reported net revenues of US$1,417.3 million, representing a 19.8% increase year over year. The growth was mainly driven by the increase in net revenues from the Company's new educational business initiatives.

Operating Costs and Expenses

Operating costs and expenses for the quarter were US$1,237.0 million, representing a 16.9% increase year over year.

• Cost of revenues increased by 23.4% year over year to US$656.2 million.
• Selling and marketing expenses increased by 9.1% year over year to US$198.8 million.
• General and administrative expenses for the quarter increased by 10.8% year over year to US$382.1 million.

Total share-based compensation expenses, which were allocated to related operating costs and expenses, increased by 30.9% to US$21.1 million in the third fiscal quarter of 2026.

Operating Income and Operating Margin

Operating income was US$180.3 million, representing a 44.8% increase year over year. Non-GAAP income from operations for the quarter, excluding share-based compensation expenses and amortization of intangible assets resulting from business acquisitions, was US$202.9 million, representing a 42.8% increase year over year.

Operating margin for the quarter was 12.7%, compared to 10.5% in the same period of the prior fiscal year. Non-GAAP operating margin, which excludes share-based compensation expenses and amortization of intangible assets resulting from business acquisitions, for the quarter was 14.3%, compared to 12.0% in the same period of the prior fiscal year.

Net Income and Net Income per ADS

Net income attributable to New Oriental for the quarter was US$126.8 million, representing a 45.3% increase year over year. Basic and diluted net income per ADS attributable to New Oriental were US$0.80 and US$0.79, respectively.

Non-GAAP Net Income and Non-GAAP Net Income per ADS

Non-GAAP net income attributable to New Oriental for the quarter, excluding share-based compensation expenses, amortization of intangible assets resulting from business acquisitions,  (gain)/loss from fair value change of investments, loss from equity method investments, gain on disposals of investments and others, as well as tax effects on non-GAAP adjustments, was US$152.2 million, representing a 34.3% increase year over year. Non-GAAP basic and diluted net income per ADS attributable to New Oriental were US$0.97 and US$0.95, respectively.

Cash Flow

Net operating cash outflow for the third fiscal quarter of 2026 was approximately US$7.5 million and capital expenditures for the quarter were US$68.8 million.

Balance Sheet

As of February 28, 2026, New Oriental had cash and cash equivalents of US$1,783.4 million. In addition, the Company had US$1,491.7 million in term deposits and US$1,953.2 million in short-term investments.

New Oriental's deferred revenue, which represents cash collected upfront from customers and related revenue that will be recognized as the services or goods are delivered, at the end of the third quarter of fiscal year 2026 was US$1,885.9 million, an increase of 7.8% as compared to US$1,749.9 million at the end of the third quarter of fiscal year 2025.

Financial Results for the Nine Months Ended February 28, 2026

For the first nine months of fiscal year 2026, New Oriental reported net revenues of US$4,131.8 million, representing a 13.0% increase year over year.

Operating income was US$557.5 million, representing a 27.6% increase year over year. Non-GAAP operating income, excluding share-based compensation expenses, amortization of intangible assets resulting from business acquisitions for the first nine months of fiscal year 2026 was US$627.6 million, representing a 32.8% increase year over year.

Operating margin for the first nine months of fiscal year 2026 was 13.5%, compared to 11.9% for the same period of the prior fiscal year. Non-GAAP operating margin, which excludes share-based compensation expenses and amortization of intangible assets resulting from business acquisitions, for the first nine months of fiscal year 2026, was 15.2%, compared to 12.9% for the same period of the prior fiscal year.

Net income attributable to New Oriental for the first nine months of fiscal year 2026 was US$413.0 million, representing a 13.3% increase year over year. Basic and diluted net income per ADS attributable to New Oriental for the first nine months of fiscal year 2026 amounted to US$2.61 and US$2.58, respectively.

Non-GAAP net income attributable to New Oriental, excluding share-based compensation expenses, amortization of intangible assets resulting from business acquisitions, (gain)/loss from fair value change of investments, loss from equity method investments, gain on disposals of investments and others, as well as tax effects on non-GAAP adjustments, for the first nine months of fiscal year 2026 was US$483.3 million, representing a 15.4% increase year over year. Non-GAAP basic and diluted net income per ADS attributable to New Oriental for the first nine months of fiscal year 2026 amounted to US$3.05 and US$3.02, respectively.

Outlook for the Fourth Quarter of the Fiscal Year 2026

New Oriental expects total net revenues in the fourth quarter of the fiscal year 2026 (March 1, 2026 to May 31, 2026) to be in the range of US$1,429.6 million to US$1,466.9 million, representing year over year increase in the range of 15% to 18%.  

Driven by encouraging growth across various business lines, New Oriental raises the full year guidance of total net revenues in the fiscal year 2026 (June 1, 2025 to May 31, 2026) to be in the range of US$5,561.4 million to US$5,598.7 million, representing a year over year increase in the range of 13% to 14%.

This forecast reflects New Oriental's current and preliminary view, which is subject to change. The forecast is based on the current USD/RMB exchange rate, which is also subject to change.

Conference Call Information

New Oriental's management will host an earnings conference call at 8 AM on April 22, 2026, U.S. Eastern Time (8 PM on April 22, 2026, Beijing/Hong Kong Time). 

Please register in advance of the conference, using the link provided below. Upon registering, you will be provided with participant dial-in numbers, and unique personal PIN.

Conference call registration link: 
https://register-conf.media-server.com/register/BI2d1b37f83b4645f08b73fdd17af502f3.

It will automatically direct you to the registration page of "New Oriental FY2026 Q3 Earnings Conference Call" where you may fill in your details for RSVP.

In the 10 minutes prior to the call start time, you may use the conference access information (including dial in number(s) and personal PIN) provided in the confirmation email received at the point of registering.

Joining the conference call via a live webcast:

Additionally, a live and archived webcast of the conference call will be available at http://investor.neworiental.org.

Listening to the conference call replay:

A replay of the conference call may be accessed via the webcast on-demand by registering at https://edge.media-server.com/mmc/p/7x5ve8hp first. The replay will be available until April 22, 2027.

About New Oriental

New Oriental is a provider of private educational services in China offering a wide range of educational programs, services and products to a varied student population throughout China. New Oriental's program, service and product offerings mainly consist of educational services and test preparation courses, private label products and livestreaming e-commerce, overseas study consulting services, and educational materials and distribution. New Oriental is listed on NYSE (NYSE: EDU) and SEHK (9901.SEHK), respectively. New Oriental's ADSs, each of which represents ten common shares, are listed and traded on the NYSE. The Hong Kong-listed shares are fully fungible with the ADSs listed on NYSE.

For more information about New Oriental, please visit http://www.neworiental.org/english/.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the outlook for the fourth quarter and full year of fiscal year 2026, quotations from management in this announcement, as well as New Oriental's strategic and operational plans, contain forward-looking statements. New Oriental may also make written or oral forward-looking statements in its reports filed or furnished to the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about New Oriental's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's ability to effectively and efficiently manage changes of its existing business and new business; its ability to execute its business strategies; uncertainties in relation to the interpretation and implementation of or proposed changes to, the PRC laws, regulations and policies regarding the private education industry; its ability to attract students without a significant increase in course fees; its ability to maintain and enhance its "New Oriental" brand; its ability to maintain consistent teaching quality throughout its school network, or service quality throughout its brand; its ability to achieve the benefits it expects from recent and future acquisitions; the outcome of ongoing, or any future, litigation or arbitration, including those relating to copyright and other intellectual property rights; competition in the private education sector and livestreaming e-commerce business in China; the continuing efforts of its senior management team and other key personnel, health epidemics and other outbreaks in China; and general economic conditions in China. Further information regarding these and other risks is included in its annual report on Form 20-F and other documents filed with the Securities and Exchange Commission. New Oriental does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release and in the attachments is as of the date of this press release, and New Oriental undertakes no duty to update such information, except as required under applicable law.

About Non-GAAP Financial Measures

To supplement New Oriental's consolidated financial results presented in accordance with GAAP, New Oriental uses the following measures defined as non-GAAP financial measures by the SEC: net income excluding share-based compensation expenses, amortization of intangible assets resulting from business acquisitions, (gain)/loss from fair value change of investments, loss/(gain) from equity method investments, impairment of long-term investments and goodwill, gain on disposals of investments and others, as well as tax effects on non-GAAP adjustments; operating income excluding share-based compensation expenses, amortization of intangible assets resulting from business acquisitions, and impairment of goodwill; operating margin excluding share-based compensation expenses, amortization of intangible assets resulting from business acquisitions, and impairment of goodwill; and basic and diluted net income per ADS and per share excluding share-based compensation expenses, amortization of intangible assets resulting from business acquisitions, loss/(gain) from fair value change of investments, loss/(gain) from equity method investments, impairment of long-term investments and goodwill, gain on disposals of investments and others, as well as tax effects on non-GAAP adjustments. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. For more information on these non-GAAP financial measures, please see the tables captioned "Reconciliations of non-GAAP measures to the most comparable GAAP measures" set forth at the end of this release.

New Oriental believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance and liquidity by excluding from each non-GAAP measure certain items that may not be indicative of its operating performance from a cash perspective. New Oriental believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to New Oriental's historical performance and liquidity. New Oriental believes these non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making. A limitation of using these non-GAAP measures is that they exclude from each non-GAAP measure certain items that have been and will continue to be for the foreseeable future a significant recurring expense in its business. Management compensates for these limitations by providing specific information regarding the GAAP amounts excluded from each non-GAAP measure. The accompanying tables have more details on the reconciliations between GAAP financial measures that are most directly comparable to non-GAAP financial measures.

Contacts

Microsoft (MSFT.US) announced that, as part of its 'Frontier Transformation' initiative, Microsoft 365 E7 Frontier Suite, as a Wave 3 of Microsoft Copilot, will be officially launched in Hong Kong on 1 May.

Microsoft 365 E7 integrates Microsoft 365 Copilot, Work IQ and Agent 365, while featuring enterprise-grade security, identity management and AI agent governance capabilities.

AIA (01299.HK) is leveraging Microsoft’s AI platform to implement a comprehensive agentic AI strategy across its operations, encompassing AI agent-powered product training, sales object management & knowledge access, automated claims processing and customer self-service.
~

AASTOCKS Financial News
Website: www.aastocks.com

Apple (AAPL.US) announced a major leadership transition after market closed on Monday (20th), BofA Securities issued a research report saying. Tim Cook will become Executive Chairman of the Board, while John Ternus, currently senior vice president of Hardware Engineering, will succeed as CEO, effective 1 September 2026.

The broker believed that the move signals positively for Apple's long-term vision, as Ternus has worked at Apple for more than 20 years and previously led hardware development across iPhone, iPad, Mac, Apple Watch, AirPods and Vision Pro.

BofA Securities viewed Cook's continuation as Chairman and his ongoing engagement with global policymakers as a positive sign for a smooth transition.

2027 will mark the 20th anniversary of iPhone and could be a big product year, BofA Securities added. The broker estimated the transition to proceed smoothly, similar to Apple's previous senior leadership changes. Therefore, BofA Securities kept rating at Buy on Apple, with a target price of US$325.
~


AASTOCKS Financial News
Website: www.aastocks.com

Tesla (TSLA.US) is set to release its 1Q26 results this week, and investors are likely to lay their eyes on the progress of the company's robotaxi deployment, BofA Securities wrote in its report.

Last Saturday, BofA Securities expressed that it was encouraged by Tesla's announcement that it had expanded its robotaxi services to Dallas and Houston, bringing the total number of deployed cities to four, a step closer to its target of reaching nine cities in 1H26.

BofA Securities also predicts investor attention to go to the progress in scaling up production of the Optimus humanoid robot, which forms a key component of Tesla's USD20 billion capital expenditure plan for this year. While the broker doesn't expect Optimus to make a meaningful contribution in the near term, it still sees substantial long-term potential.

Tesla's rating remains Buy, alongside a target price of USD460. BofA Securities believes the company is in the early stages of monetizing its autonomous driving capabilities.
~



AAStocks Financial News
Web Site: www.aastocks.com

美國馬裡蘭州羅克維爾市和中國蘇州2026年4月22日 /美通社/ -- 致力於在腫瘤等領域開發創新藥物的領先的生物醫藥企業——亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）宣布，公司三個重點品種的六項臨床研究入選2026年美國臨床腫瘤學會（ASCO）年會，其中三項獲快速口頭報告。這三個重點品種分別為中國首個獲批上市的第三代BCR-ABL抑制劑奧雷巴替尼（商品名：耐立克^®）、中國首個獲批上市的國產原創Bcl-2選擇性抑制劑利沙托克拉（商品名：利生妥^®）和MDM2-p53抑制劑Alrizomadlin（APG-115）。

一年一度的ASCO年會是全球腫瘤領域最重要、最權威的學術交流盛會，將展示當前國際最前沿的臨床腫瘤學科研成果和腫瘤治療技術。本屆ASCO年會將於5月29日至6月2日（美國當地時間）在芝加哥McCormick會議中心以線上線下結合的形式舉辦。

亞盛醫藥首席醫學官翟一帆博士表示：「這將是亞盛醫藥連續第九年亮相ASCO年會，很高興能夠又一次站在這一國際頂尖學術舞台展示公司的全球創新與研發實力。今年，公司在研品種有多項研究入選，其中三項研究獲快速口頭報告，再次印證了國際學術界對公司原研品種臨床價值的高度認可。我們期待在會議期間為大家分享更為詳實的數據，並繼續加速全球臨床開發進程，早日為患者帶來更多治療選擇。」

亞盛醫藥將在本屆ASCO年會展示的臨床研究進展包括：

快速口頭報告

Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)
奧雷巴替尼（HQP1351）聯合貝林妥歐單抗治療淋系急變期慢性髓細胞白血病（CML-LBP）或費城染色體陽性B細胞前體急性淋巴細胞白血病（Ph+ BCP-ALL）患者
摘要編號：6513
展示形式：快速口頭報告
分會場標題：血液系統惡性腫瘤——白血病、骨髓增生異常綜合征及同種異體移植（Hematologic Malignancies—Leukemia, MDS, and Allotransplant）
報告時間：
2026年5月30日 13:15–14:45（美國中部時間）
2026年5月31日 凌晨2:15–3:45（北京時間）
第一作者：Elias Jabbour, MD，美國德克薩斯大學MD安德森癌症中心白血病科

Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML)
奧雷巴替尼（HQP1351）二線治療慢性期慢性髓細胞白血病（CP-CML）患者的最新療效和安全性數據
摘要編號：6510
展示形式：快速口頭報告
分會場標題：血液系統惡性腫瘤——白血病、骨髓增生異常綜合征及同種異體移植（Hematologic Malignancies—Leukemia, MDS, and Allotransplant）
報告時間：
2026年5月30日 13:15–14:45（美國中部時間）
2026年5月31日 凌晨2:15–3:45（北京時間）
第一作者：黎緯明教授，華中科技大學同濟醫學院附屬協和醫院血液科

Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)
Alrizomadlin（APG-115）單藥或聯合利沙托克拉（APG-2575）治療復發/轉移性橫紋肌肉瘤（RMS）或其他軟組織肉瘤（STSs）兒童患者
摘要編號：10012
展示形式：快速口頭報告
分會場標題：兒童腫瘤II（Pediatric Oncology II）
報告時間：
2026年5月30日 8:00–9:30（美國中部時間）
2026年5月30日 21:00–22:30（北京時間）
第一作者：張翼鷟教授，中山大學腫瘤防治中心兒童腫瘤科，華南腫瘤學國家重點實驗室，腫瘤醫學協同創新中心

壁報展示

Updated clinical and translational results of Olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient tumors
奧雷巴替尼（HQP1351）治療琥珀酸脫氫酶缺陷型（SDH-）腫瘤患者的最新臨床和轉化研究結果
摘要編號：11539
展示形式：壁報展示
分會場標題：肉瘤（Sarcoma）
報告時間：
2026年6月1日 13:30–16:30（美國中部時間）
2026年6月2日 凌晨2:30–5:30（北京時間）
第一作者：邱海波教授，中山大學腫瘤防治中心，華南腫瘤學國家重點實驗室，腫瘤醫學協同創新中心

A phase 3 study of Olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress
奧雷巴替尼（HQP1351）治療慢性期慢性髓細胞白血病患者的III期臨床研究：正在進行中的POLARIS-2試驗
摘要編號：TPS6608
展示形式：壁報展示
分會場標題：血液系統惡性腫瘤——白血病、骨髓增生異常綜合征及同種異體移植（Hematologic Malignancies—Leukemia, MDS, and Allotransplant）
報告時間：
2026年6月1日 9:00–12:00（美國中部時間）
2026年6月1日 22:00–次日凌晨1:00（北京時間）
第一作者：Elias Jabbour, MD，美國德克薩斯大學MD安德森癌症中心白血病科

A global multicenter, open-label, randomized, phase 3 registrational study of Lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress
利沙托克拉（APG-2575）治療既往經治慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者的全球多中心、開放性、隨機、III期注冊臨床研究：正在進行中的GLORA試驗
摘要編號：TPS7101
展示形式：壁報展示
分會場標題：血液系統惡性腫瘤——淋巴瘤和慢性淋巴細胞白血病（Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia）
報告時間：
2026年6月1日 9:00–12:00（美國中部時間）
2026年6月1日 22:00–次日凌晨1:00（北京時間）
第一作者：Matthew Steven Davids, MD，美國丹娜法伯癌症研究院

關於亞盛醫藥

亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）是一家綜合性的全球生物醫藥企業，致力於研發、生產和商業化創新藥，以解決腫瘤領域全球患者尚未滿足的臨床需求。公司已建立豐富的創新藥產品管線，包括抑制Bcl-2和 MDM2-p53 等細胞凋亡通路關鍵蛋白的抑制劑、新一代針對癌症治療中出現的激酶突變體的抑制劑以及蛋白降解劑。

公司核心品種耐立克^®是中國首個獲批上市的第三代BCR-ABL抑制劑，已獲批用於治療伴有T315I突變的慢性髓細胞白血病慢性期（CML-CP）和加速期（CML-AP）患者，以及對一代和二代TKI耐藥和/或不耐受的CML-CP成年患者。該藥物所有獲批適應症均已被納入中國國家醫保藥品目錄（NRDL）。目前，亞盛醫藥正在開展耐立克^®三項全球注冊III期臨床研究，分別為：獲美國FDA和歐洲EMA許可的評估耐立克^®治療新診斷費城染色體陽性急性淋巴細胞白血病（Ph+ ALL）患者POLARIS-1研究；獲美國FDA和歐洲EMA許可的評估耐立克^®治療經治CML-CP成年患者的POLARIS-2研究；評估耐立克^®治療SDH-缺陷型GIST患者的POLARIS-3研究。

公司另一重磅品種利生妥^®是一款用於治療多種血液系統惡性腫瘤的新型Bcl-2抑制劑。利生妥^®已獲中國國家藥品監督管理局（NMPA）批准，用於治療既往至少接受過一種包括布魯頓酪氨酸激酶（BTK）抑制劑在內的系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者。目前，亞盛醫藥正在開展利生妥^®四項全球注冊III期臨床研究，分別為：獲美國FDA和歐洲MEA許可的評估利生妥^®聯合BTK抑制劑治療既往接受BTK抑制劑治療超過12個月且應答不佳的CLL/SLL患者的GLORA研究；評估利生妥^®一線治療初治CLL/SLL患者的GLORA-2研究；評估利生妥^®一線治療新診斷老年或不耐受的AML患者的GLORA-3研究；以及獲美國FDA和歐洲EMA許可的評估利生妥^®一線治療新診斷中高危MDS患者的GLORA-4研究。

憑借強大的研發能力，亞盛醫藥已在全球范圍內進行知識產權布局，並與武田、阿斯利康、默沙東、輝瑞、信達等眾多領先的生物制藥公司達成全球合作，同時與丹娜法伯癌症研究院、梅奧醫學中心、美國國家癌症研究所和密西根大學等學術機構建立研發合作關系。如需了解更多信息，請訪問 https://ascentage.com/

前瞻性聲明

本新聞稿包含根據美國《1995年私人證券訴訟改革法案》，以及經修訂的《1933年證券法》第27A條和《1934年證券交易法》第21E條所界定的前瞻性陳述。除歷史事實陳述外，本新聞稿中的所有內容均可能構成前瞻性陳述，包括亞盛醫藥對未來事件、經營成果或財務狀況所發表的意見、預期、信念、計劃、目標、假設或預測。

這些前瞻性陳述受到諸多風險和不確定性的影響，具體內容已在亞盛醫藥向美國證券交易委員會（SEC）提交的文件中詳細說明，包括2025年1月21日提交的經修訂的F-1表格注冊說明書和2025年4月16日提交的20-F表格中的「風險因素」和「關於前瞻性聲明的警示聲明」章節、2019年10月16日提交的首次發行上市招股書中的「前瞻性聲明」、「風險因素」章節，以及我們不時向SEC或HKEX提交的其他文件。這些因素可能導致實際業績、運營水平、經營成果或成就與前瞻性陳述中明示或暗示的信息存在重大差異。本前瞻性聲明中的陳述不構成公司管理層的利潤預測。

因此，該等前瞻性陳述不應被視為對未來事件的預測。本新聞稿中的前瞻性陳述僅基於亞盛醫藥當前對未來發展及其潛在影響的預期和判斷，且僅代表截至陳述發表之日的觀點。無論出現新信息、未來事件或其他情況，亞盛醫藥均無義務更新或修訂任何前瞻性陳述。

CHENGDU, China, April 22, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 29 to June 2. In this meeting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) will present results from three clinical studies, including data from its TROP2 ADC sacituzumab tirumotecan (sac-TMT, 佳泰莱^®), next-generation selective RET inhibitor lunbotinib fumarate (A400/EP0031, 宁泰莱^®[1]) and novel ADC SKB500. The abstracts for these studies will be published on the ASCO official website on May 21, 2026, local time.

Detailed information on the studies selected for 2026 ASCO is as follows:

Title: Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC): Results from the randomized, controlled phase III OptiTROP-Lung05 study
Presentation Type: Oral
Abstract Number: 8506
Session Date and Time: May 29, 3:12 PM-3:24 PM CDT | Lung Cancer-Non-Small Cell Metastatic

Title: Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC)
Presentation Type: Oral
Abstract Number: 8505
Session Date and Time: May 29, 2:36 PM-2:48 PM CDT | Lung Cancer-Non-Small Cell Metastatic

Title: An open-label, first-in-human study of SKB500 in patients with locally advanced or metastatic solid tumors
Presentation Type: Rapid oral
Abstract Number: 3011
Session Date and Time: June 2, 9:57 AM-10:03 AM CDT | Molecularly Targeted Agents and Tumor Biology

About sac-TMT

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: 1) unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting);2) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy; 3) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) BC who have received prior ET and at least one line of chemotherapy in advanced setting. The first two indications above have been included in China's National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the NMPA.

Sac-TMT is the world's first TROP2 ADC drug approved for marketing in lung cancer. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD is evaluating 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About A400/EP0031

A400/EP0031 novel next-generation selective RET inhibitor for NSCLC, medullary thyroid cancer (MTC) and other solid tumors with a high prevalence of RET alterations. The NDA of A400/EP0031 has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of adult patients with RET-fusion positive locally advanced or metastatic NSCLC. The Company is also conducting a Phase Ib/II clinical study in China for the treatment of RET-positive solid tumors.

In March 2021, the Company granted Ellipses Pharma Limited, a U.K.-based international oncology drug development company, an exclusive license to develop, manufacture and commercialize this agent outside Greater China and certain Asian countries. In April 2024, A400/EP0031 was cleared by the Food and Drug Administration (FDA) to progress into a Phase II clinical trial (NCT05443126) which is currently recruiting in the United States, United Kingdom, Europe and United Arab Emirates, where it is being evaluated as a monotherapy and in combination with chemotherapy in RET fusion positive NSCLC.

About SKB500

SKB500, a novel, proprietary ADC developed via the OptiDC™ platform, is designed to leverage specific target biology through a validated target combined with a differentiated payload-linker strategy. In preclinical investigations, SKB500 demonstrated a favorable therapeutic window with robust efficacy and manageable safety profiles across multiple advanced solid tumors.

Currently, a Phase II exploratory study of SKB500 in combination with immunotherapy with or without chemotherapy as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) is ongoing in China.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.